Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CTJD | ISIN: KYG5252B1023 | Ticker-Symbol: 64Z
Frankfurt
27.06.25 | 08:02
4,800 Euro
-4,95 % -0,250
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
KEYMED BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
KEYMED BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,8805,20020:33
4,9005,15020:32

Aktuelle News zur KEYMED BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoKEYMED BIO-B (02162): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2025-
19.06.KEYMED BIO-B (02162): NEXT DAY DISCLOSURE RETURN-
19.06.KEYMED BIO-B (02162): COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE-
13.06.Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine575CHENGDU, China, June 13, 2025 /PRNewswire/ -- On June 12, Keymed Biosciences Inc. (HKEX: 02162) announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases...
► Artikel lesen
11.06.KEYMED BIO-B Places Shrs at 6.5% Discount to Raise HKD850M+ Net Proceeds; Controlling Shareholder Cuts Stake1
11.06.KEYMED BIO-B (02162): (1) PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE AND (2) SALE OF SHARES BY THE TOP-UP ...1
KEYMED BIOSCIENCES Aktie jetzt für 0€ handeln
28.04.KEYMED BIO-B (02162): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING-
28.04.KEYMED BIO-B (02162): NOTICE OF ANNUAL GENERAL MEETING2
28.04.KEYMED BIO-B (02162): (1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) RE-APPOINTMENT OF AUDITOR; AND (4) ...-
28.04.KEYMED BIO-B (02162): 2024 ANNUAL REPORT-
27.04.Keymed Biosciences gibt die IND-Genehmigung für CM518D1 durch die National Medical Products Administration of China zur Behandlung von Solide Tumoren bekannt77CHENGDU, China, 27. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" oder das "Unternehmen") gab vor kurzem bekannt, dass CM518D1, ein...
► Artikel lesen
25.04.Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors299CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed...
► Artikel lesen
07.04.Keymed Biosciences: Daten aus Phase-III-Studie zu Stapokibart gegen saisonale allergische Rhinitis in Nature Medicine veröffentlicht228CHENGDU, China, 7. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" oder "Unternehmen") gab heute bekannt, dass die renommierte medizinische...
► Artikel lesen
05.04.Keymed Biosciences: The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine635CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published...
► Artikel lesen
26.03.Keymed Biosciences Announces Annual Results of 2024132CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate...
► Artikel lesen
24.03.KEYMED BIO-B (02162): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE1
24.03.KEYMED BIO-B (02162): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS-
24.03.KEYMED BIO-B (02162): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024; AND CHANGE OF COMPOSITION OF THE NOMINATION COMMITTEE1
12.03.KEYMED BIO-B (02162): DATE OF BOARD MEETING2
10.02.Keymed's Stapokibart approved by NMPA for seasonal allergic rhinitis1
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1